目的 探討利肺片聯(lián)合丙酸倍氯米松吸入氣霧劑治療慢性支氣管炎急性發(fā)作患者的臨床療效。方法 選取2019年6月—2021年6月在焦作市第五人民醫(yī)院就診的100例慢性支氣管肺炎患者，按照隨機(jī)數(shù)字表法將全部患者分為對(duì)照組和治療組，各包括50例患者。對(duì)照組使用丙酸倍氯米松吸入氣霧劑，100 μg/次，3次/d。治療組在對(duì)照組基礎(chǔ)上口服利肺片，0.5 g/次，3次/d。兩組連續(xù)治療2周后統(tǒng)計(jì)療效。觀(guān)察兩組治療后的臨床療效，比較兩組的主要癥狀體征消失時(shí)間、用力肺活量（FVC）、呼氣峰值流速（PEF）、第一秒用力呼氣量占用力肺活量比值（FEV1/FVC）以及患者治療前后痰液中白細(xì)胞介素-6（IL-6）、C反應(yīng)蛋白（CRP）、可溶性髓樣細(xì)胞觸發(fā)性受體-1（sTREM-1）水平。結(jié)果 治療后，治療組患者的總有效率（94.00%）明顯比對(duì)照組的總有效率（80.00%）高（P<0.05）。治療后，治療組的止咳時(shí)間、平喘時(shí)間、痰消時(shí)間短于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的FVC、PEF、FEV1/FVC均明顯升高（P<0.05）；且以治療組FVC、PEF、FEV1/FVC升高更明顯（P<0.05）。治療后，兩組的痰液中IL-6、CRP、sTREM-1水平顯著降低（P<0.05）；且以治療組痰液中IL-6、CRP、sTREM-1水平降低更明顯（P<0.05）。結(jié)論 利肺片聯(lián)合丙酸倍氯米松吸入氣霧劑治療慢性支氣管炎的療效確切，能改善患者臨床癥狀和肺功能，減輕肺部炎癥反應(yīng)，且安全性較好。

Objective To investigate the clinical efficacy of Lifei Tablets combined with Beclometasone Dipropionate Inhalation Aerosol in treatment of acute attack of chronic bronchitis. Methods Patients (100 cases) with acute attack of chronic bronchitis in Jiaozuo Fifth People’s Hospital from June 2019 to June 2021 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were given Beclometasone Dipropionate Inhalation Aerosol, 100 μg/time, three times daily. Patients in the treatment group were po administered with Lifei Tablets on the basis of the control group, 0.5 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and the disappearance times of main symptom, FVC, PEF, FEV1/FVC, and the levels of IL-6, CRP, and sTREM-1 in two groups were compared. Results After treatment, total effective rate of the treatment group (94.00%) was significantly higher than that of the control group (80.00%) (P<0.05). After treatment, the cough relieving time, asthma relieving time and phlegm eliminating time in the treatment group were shorter than those in the control group (P<0.05). After treatment, the FVC, PEF, and FEV1/FVC of two groups were significantly increased P<0.05), and the FVC, PEF, and FEV1/FVC in the treatment group were significantly higher than those in the control groups (P<0.05). After treatment, the levels of IL-6, CRP, and sTREM-1 in sputum of two groups were significantly decreased (P<0.05). The levels of IL-6, CRP, and sTREM-1 in sputum of the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Lifei Tablets combined with Beclometasone Dipropionate Inhalation Aerosol is effective in the treatment of acute attack of chronic bronchitis, can improve clinical symptoms and pulmonary function, reduce inflammatory reaction, with good safety.

R974

河南省醫(yī)學(xué)科技攻關(guān)項(xiàng)目（2018020858）